Physician profile
Eugenio Angueira-Serrano
NPI 1578621702
$602,900.67
in general payments reported to CMS, 2019-2025
63 companies · $110K in 2025
The $110K reported for 2025 was more than what 98% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $132K · 2020: $62K · 2021: $114K · 2022: $80K · 2023: $51K · 2024: $53K · 2025: $110K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $113K · Honoraria: $58K · Food and Beverage: $21K · Travel and Lodging: $17K · Consulting Fee: $5,077 · Education: $20.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $112,802.96 |
| Honoraria | $58,239.30 |
| Food and Beverage | $21,169.60 |
| Travel and Lodging | $16,960.96 |
| Consulting Fee | $5,077.09 |
| Education | $20.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $147,815.97 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $96,095.62 | 2019-2025 | Korlym |
| Lilly USA, LLC | $64,848.87 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $60,575.58 | 2019-2025 | |
| Amgen INC. | $54,847.55 | 2019-2025 | Repatha, Tepezza, Evenity |
| Esperion Therapeutics, INC. | $25,759.62 | 2020-2025 | Nexletol |
| Xeris Pharmaceuticals, INC. | $25,607.49 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23,579.18 | 2019-2025 | Jardiance, Synjardy |
| Recordati_rare_diseases_inc. | $17,719.05 | 2021-2025 | Isturisa, Signifor Lar |
| Amarin Pharma, INC. | $16,619.15 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $11,616.74 | 2021-2025 | |
| Ascendis Pharma Endocrinology INC | $9,535.42 | 2023-2025 | Yorvipath |
| Intuity Medical INC | $8,660.18 | 2022 | |
| Chiesi USA, INC. | $6,695.46 | 2023-2025 | Mycapssa |
| Mannkind Corporation | $5,220.87 | 2019-2025 | Afrezza, V-Go |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $3,625.53 | 2019-2020 | |
| Madrigal Pharmaceuticals | $3,042.50 | 2024-2025 | Rezdiffra, Resmetirom |
| Cequr Corporation | $2,792.43 | 2023-2025 | Cequr Simplicity |
| Zealand Pharma US, INC. | $2,369.99 | 2020-2022 | |
| Abbvie INC. | $2,133.14 | 2019-2025 | Synthroid, Creon |
| Insulet Corporation | $1,864.60 | 2019-2025 | Omnipod |
| Astrazeneca Pharmaceuticals Lp | $1,637.83 | 2019-2025 | Lokelma, Farxiga |
| Novartis Pharmaceuticals Corporation | $1,071.07 | 2022-2025 | |
| Radius Health, INC. | $1,050.68 | 2019-2025 | |
| Abbott Laboratories | $849.77 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Dexcom, INC. | $687.36 | 2021-2025 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Kyowa Kirin, INC. | $505.75 | 2023-2025 | Crysvita |
| Amneal Pharmaceuticals LLC | $490.25 | 2019-2025 | Unithroid |
| Merck Sharp & Dohme LLC | $471.07 | 2019-2022 | |
| Tandem Diabetes Care, INC. | $455.72 | 2019-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Lifescan, INC. | $424.11 | 2020-2023 | |
| Antares Pharma, INC. | $385.36 | 2019-2024 | Xyosted, Tlando, Nocdurna |
| Shire North American Group INC | $347.16 | 2019 | |
| Becton, Dickinson and Company | $336.85 | 2019-2022 | |
| Ibsa Pharma INC. | $329.21 | 2019-2025 | Tirosint, Licart, Tirosint |
| Ultragenyx Pharmaceutical INC. | $271.14 | 2021-2022 | |
| Valeritas, INC. | $262.03 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $238.41 | 2019-2025 | Evkeeza |
| Sequel Med Tech, LLC | $222.24 | 2025 | Twiist |
| Pfizer INC. | $208.94 | 2019-2025 | |
| Merz North America, INC. | $188.18 | 2019 | |
| Embecta Corp. | $174.84 | 2023-2024 | Bd Nano 2nd Gen Pen Needle |
| Amphastar Pharmaceuticals, INC. | $162.02 | 2024-2025 | |
| Beta Bionics, INC. | $161.44 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $117.14 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $104.21 | 2023-2024 | Strensiq |
| Halozyme INC | $101.42 | 2023 | |
| Nestle Healthcare Nutrition INC. | $96.85 | 2020-2021 | |
| Medtronic, INC. | $76.26 | 2023-2024 | Minimed 780g, Mycarelink |
| Ionis Pharmaceuticals, INC. | $72.36 | 2025 | Tryngolza |
| Janssen Scientific Affairs, LLC | $66.78 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $58.34 | 2019-2020 | |
| Horizon Therapeutics Plc | $50.04 | 2020-2023 | Tepezza |
| Eusa Pharma (US) LLC | $44.61 | 2022 | |
| Neurocrine Biosciences, INC. | $43.98 | 2025 | |
| Ascensia Diabetes Care US INC. | $31.41 | 2024 | |
| Biogen, INC. | $19.89 | 2021 | |
| Cardinal Health 414 LLC | $18.22 | 2024 | |
| Roche Diabetes Care, INC. | $16.21 | 2021 | |
| Clarus Therapeutics INC. | $13.56 | 2021 | |
| Allergan, INC. | $13.02 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eugenio Angueira-Serrano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.